Search clinical trials for: Progesterone Receptor Negative

Total 23854 results

OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
AstraZeneca

Active, not recruiting

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Metastatic Triple Negative Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Canada, Czechia, Poland, France, Korea, Republic of, Germany, Taiwan, Portugal, Netherlands, Ireland
University of California, Irvine
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

Breast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast Cancer

United States
ETOP IBCSG Partners Foundation
Breast International Group

Completed

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer (PYTHIA)

Metastatic Breast Cancer

United Kingdom, Belgium, Italy
Thomas Jefferson University
National Cancer Institute (NCI)

Suspended

Intermittent Fasting for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Hormone Receptor Positive Breast Carcinoma | Breast Ductal Carcinoma in Situ | HER2 Negative Breast Carcinoma

United States
Daiichi Sankyo

Completed

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

HER2-negative Breast Cancer | HER2-low Breast Cancer | Hormone-receptor-positive Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (BioItaLEE)

Breast Cancer

Italy
Dana-Farber Cancer Institute
Pfizer

Completed

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Breast Cancer

United States
Relay Therapeutics, Inc.

Active, not recruiting

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Unresectable Solid Tumor | PIK3CA Mutation

United States
University of Chicago

Active, not recruiting

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

Breast Cancer

United States
Compugen Ltd
Bristol-Myers Squibb

Active, not recruiting

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Breast Cancer | Ovarian Cancer | Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Advanced Cancer | Colo-rectal Cancer | Ovarian Neoplasm | Neoplasm Malignant | Lung Neoplasm

United States
Ente Ospedaliero Ospedali Galliera
Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Istituto Di Ricerche... and other collaborators

Terminated

Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer (EXPERT)

Ovarian Cancer

Italy
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

Advanced, Androgen Receptor Positive Triple Negative Breast Cancer

United States, Spain, Belgium, Canada, Ireland, United Kingdom, Italy
Northwell Health
Takeda

Active, not recruiting

Adjunctive Vortioxetine in Schizophrenia (AVIS)

Schizophrenia | Negative Symptoms

United States
UNICANCER
ARCAGY/ GINECO GROUP; SOLTI Breast Cancer Research Group

Active, not recruiting

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF)

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer | a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status

France
Institut Curie
AstraZeneca

Completed

Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) (RadioPARP)

Radiotherapy Side Effect | Breast Neoplasm Malignant Female | Breast Neoplasms, Triple-Negative

France
Pfizer

Completed

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

Breast Cancer Metastatic

Argentina, United Kingdom
Accutar Biotechnology Inc

Terminated

A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
Kite, A Gilead Company

Terminated

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Multiple Myeloma | Ovarian Cancer | Fallopian Tube Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma

United States
Novartis Pharmaceuticals

Completed

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (BOLERO-5)

Advanced Breast Cancer

China
CytomX Therapeutics

Completed

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Neoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 Negative

United States, Spain, Korea, Republic of
Arvinas Estrogen Receptor, Inc.
Pfizer

Active, not recruiting

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (TACTIVE-E)

Breast Cancer

United States, Spain
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IIIC Breast Cancer | HER2/Neu Negative | Stage III Breast Cancer | Postmenopausal | Estrogen Receptor Status

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Terminated

A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older

Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen Receptor Positive Breast Cancer | Node-negative Breast Cancer

United States
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); Breast International Group

Active, not recruiting

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (TEXT)

Breast Cancer

United States, Australia, Switzerland, Italy, Canada, Belgium, Peru, United Kingdom, Egypt, New Zealand, Slovenia, South Africa, Sweden, Hungary, India, Germany, Brazil
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia... and other collaborators

Active, not recruiting

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States, Canada, Switzerland
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

HR-positive, HER2-negative Breast Neoplasms

China
University of Alabama at Birmingham
Novartis Pharmaceuticals; Tracon Pharmaceuticals Inc.

Completed

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center

Withdrawn

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Hormone Receptor Positive Breast Adenocarcinoma | Metastatic HER2 Negative Breast Adenocarcinoma

United States
Eisai Inc.

Completed

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Cancer, Breast | Breast Cancer Female | Estrogen Receptor Positive Tumor | Breast Adenocarcinoma | ER Positive | Estrogen-receptor Positive Breast Cancer

France, United Kingdom, United States
Eisai Co., Ltd.

Active, not recruiting

Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Breast Neoplasms

Japan
Royal Marsden NHS Foundation Trust
Pfizer; Breast Cancer Now

Active, not recruiting

Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo)

Gastric Cancer | Triple Negative Breast Cancer | Lobular Breast Carcinoma | CDH1 Gene Mutation

United Kingdom
Georgetown University
Pfizer

Active, not recruiting

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Metastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone Receptor Positive Breast Cancer

United States
Washington University School of Medicine
Pfizer

Active, not recruiting

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Breast Neoplasms

United States
Pfizer

Completed

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

Breast Cancer | Breast Neoplasms | Breast Tumors | Breast Carcinoma | Cancer of Breast

India
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Breast Cancer

Japan, Poland, United States, Australia, Belgium, Brazil, Canada, China, Colombia, Costa Rica, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Taiwan, Ukr... and more
Pfizer

Completed

A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting

Breast Neoplasms

Poland
M.D. Anderson Cancer Center

Completed

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Hematopoietic and Lymphoid Cell Neoplasm | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Stage IV Lung Cancer AJCC v8 | Metastatic... and other conditions

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb; Susan G. Komen Breast Cancer Foundation

Active, not recruiting

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

Breast Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Advanced Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States
Prelude Therapeutics

Completed

A Study of PRT2527 in Participants With Advanced Solid Tumors

Sarcoma | Non-small Cell Lung Cancer | Castrate Resistant Prostate Cancer | Solid Tumors With Known MYC Amplification | Hormone Receptor Positive HER2 Negative Breast Cancer

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2-negative Breast Cancer

United States
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Advanced Breast Cancer

Japan
University of Washington
National Institute on Drug Abuse (NIDA)

Active, not recruiting

Effects of Pregnancy-associated Hormones on THC Metabolism in Women (PrECEPT)

Pregnancy Related | Cannabis Use

United States
Pfizer

Completed

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

Breast Neoplasms

United States, Canada, Spain, United Kingdom, Australia, Belgium, Korea, Republic of, Japan, Czechia, France, Germany, Hungary, Ireland, Italy, Poland, Russian Federation, Taiwan, Ukraine
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. (MONALEESA-3)

Advanced Breast Cancer

Belgium, Italy, Czechia, Hungary, Canada, Netherlands, Germany, Singapore, Australia, Denmark, Poland, Switzerland, Korea, Republic of, Spain, Thailand, Lebanon, Austria, Bulgaria, Russian Federation, Norway, Jordan, United States, ... and more
Leap Therapeutics, Inc.
Pfizer; Merck KGaA, Darmstadt, Germany

Terminated

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Solid Tumors | Advanced Triple Negative Breast Cancer | Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer | Advanced Metastatic Castration-Resistant Prostate Cancer | Advanced Platinum-Resistant Ovarian Cancer

United States
Novartis Pharmaceuticals

Completed

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III)

Carcinoma, Non-Small-Cell Lung

Belgium, Germany, Italy, France, Netherlands, Spain, Korea, Republic of, India, Brazil, Portugal
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Musculoskeletal Complications

United States

Search clinical trials for: Progesterone Receptor Negative

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations